# Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

> **NCT04623099** · PHASE4 · RECRUITING · sponsor: **University of Cincinnati** · enrollment: 132 (estimated)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT04623099
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-08
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623099, "Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04623099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*